By Manufacturing Process

Recombinant Mammalian Cell Culture (Biologic mAbs) Market Analysis

Cross-industry research covering Recombinant Mammalian Cell Culture (Biologic mAbs) across 1 market reportspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery.

1 Reports

1 Industries

Reports Covering Recombinant Mammalian Cell Culture (Biologic mAbs)

Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Medical Devices — Ophthalmic Surgery·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

The production route for anti-IGF-1R monoclonal antibodies including Tepezza (teprotumumab) and next-generation assets; CHO cell culture with Protein A affinity purification is standard, and CDMO capacity for mAb production remains tight globally despite post-pandemic capacity additions by Lonza and Samsung Biologics.

22%

Market Share

15.8%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments